Show simple item record

dc.contributor.authorHolland, Christian M A
dc.contributor.authorArbe-Barnes, Edward H
dc.contributor.authorMcGivern, Euan J
dc.contributor.authorForgan, Ruairidh M C
dc.date.accessioned2018-10-29T18:21:17Z
dc.date.available2018-10-29T18:21:17Z
dc.date.issued2018-10-29
dc.identifier.citationPhilosophy, Ethics, and Humanities in Medicine. 2018 Oct 29;13(1):14
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/284407
dc.description.abstractAbstract In an increasingly data-driven age of medicine, do companies that offer genetic testing directly to patients represent an important part of personalising care, or a dangerous threat to privacy? Should we celebrate this new mechanism of patient involvement, or fear its implications? The Universities of Oxford and Cambridge addressed these issues in the 10th annual Medical Ethics Varsity Debate, through the motion: “This House Regrets the Rise of Direct-to-Consumer Genetic Testing”. This article summarises and extends key arguments made in the debate, exploring the impacts of such genetic testing on both the individual patient and broader society, with special consideration as to whether companies can ever truly guarantee anonymity of genetic data.
dc.rightsAll Rights Reserveden
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved/en
dc.titleThe 10th Oxbridge varsity medical ethics debate-should we fear the rise of direct-to-consumer genetic testing?
dc.typeReport
dc.date.updated2018-10-29T18:21:08Z
dc.language.rfc3066en
dc.rights.holderThe Author(s).
dc.identifier.doi10.17863/CAM.31777
dc.identifier.doi10.17863/CAM.31777
rioxxterms.versionofrecord10.1186/s13010-018-0069-9


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record